Affymetrix and Vita Collaborate to Develop Microarray-based IVD Products
News Jan 03, 2006
Affymetrix Inc. and Vita Genomics have announced that Affymetrix has granted Vita Genomics and its fully owned subsidiary, Shanghai GeneCore BioTechnologies, non-exclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests for Alpha Interferon Treatment response in patients with HBV and HCV, as well as for early onset and allergic asthma in infants and young children.
The resulting microarray-based IVD products would provide clinicians with better diagnosis methods and efficient approaches for treating patients and managing these diseases.
As part of the Powered by Affymetrix™ program, Vita Genomics is able to incorporate Affymetrix' patented arrays into its molecular diagnostic assays developed to predict drug efficacy prior to treatment and assess risks to facilitate disease prevention.
"Application of using single nucleotide polymorphisms (SNP) for translational medicine studies is a trend in the pharmaceutical industry in the post Human Genome Project era," said Ellson Chen, Ph.D., president and CEO at Vita Genomics.
"We, as a discovery/specialty CRO company, are pleased to be a partner with Affymetrix, a world-leading microarray tooling company, to synergistically commercialize in vitro diagnostic products in this field."
"The microarray-based tools and applications in the Powered by Affymetrix program are accelerating the discovery and implementation of HBV, HCV and asthma companion and predictive diagnostics in this era of molecular medicine," said Robert Lipshutz, Ph. D., senior vice president, Molecular Diagnostics and Emerging Markets at Affymetrix.
"We are pleased that another innovator in the diagnostic field like Vita Genomics has adopted our proven technology platform for its in vitro diagnostic products."
"The development of companion test for certain drugs, especially for those drugs with important side-effects or drugs that only benefit subpopulation groups, is reaching the next stage with this partnership," said John Gu, Ph.D., senior vice president and Chief Business Officer of Vita Genomics.
"By using the Affymetrix platform, Vita Genomics could streamline its product development processes, expedite product registration and ultimately accelerate the time to reach the market."
Under the Powered by Affymetrix program, companies license technology from Affymetrix to develop innovative microarray products. This includes the GeneChip® System 3000Dx (GCS3000Dx).
The GCS3000Dx has been granted regulatory clearance by the U.S. Food and Drug Administration and is CE marked in the European Union for in-vitro diagnostic use.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.